...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: https://scr.zacks.co...

Nice find Fuzzy. Glad to see Zenith getting some attention. At the same time, I no longer see Resverlogix on the list of covered companies for Zacks/SCR. John Vandermosten and Zacks were the most frequent to update their Resverlogix analysis. 

BDAZ

Share
New Message
Please login to post a reply